Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Akanda Corp. is a publicly traded cannabis company focused on the cultivation, production, and distribution of medical cannabis and cannabis-derived products. The company operates primarily in the medical cannabis industry, with an emphasis on international markets where cannabis is regulated for pharmaceutical or therapeutic use. Its business model centers on supplying EU-GMP–compliant medical cannabis to regulated markets, particularly in Europe.
The company traces its origins to the development of cultivation assets in southern Africa and later expanded into European distribution. Akanda Corp. became publicly listed on Nasdaq under the ticker AKAN in 2022. Since listing, the company has faced operational and financial challenges, and public disclosures indicate periods of restructuring and reduced operating activity. Certain aspects of its recent operating status and continuity are inconclusive based on available public sources, as disclosures after 2023 show limited ongoing commercial scale.
Business Operations
Akanda Corp.’s operations have historically been organized around two primary business activities: cannabis cultivation and pharmaceutical-grade distribution. Cultivation has been conducted through its majority-owned subsidiary Bophelo Bioscience & Wellness (Pty) Ltd., which operates a licensed outdoor cultivation facility in Lesotho. This asset was positioned to produce large-scale, low-cost cannabis flower and biomass for medical and research purposes.
On the distribution side, Akanda has operated in Germany through Canmart Ltd., a pharmaceutical importer and distributor authorized to distribute medical cannabis to pharmacies. Revenue generation has primarily depended on wholesale distribution of medical cannabis products in regulated European markets. Public filings indicate that operational scale and revenue consistency have been limited, and some assets have been impaired or deconsolidated; specific current production volumes and revenue contributions are inconclusive based on available public sources.
Strategic Position & Investments
Akanda Corp.’s stated strategy has focused on leveraging low-cost cultivation in Africa combined with access to high-value European medical cannabis markets. Strategic positioning emphasized compliance with EU-GMP standards, regulatory licensing, and first-mover advantages in emerging medical cannabis jurisdictions. The company has also highlighted intentions to participate in future regulatory expansion within Europe.
Key investments have included the development of the Bophelo Bioscience & Wellness cultivation site and the acquisition of Canmart Ltd. as a German distribution platform. Beyond these assets, no material acquisitions or diversified portfolio investments have been consistently disclosed in recent filings. Due to restructuring efforts and limited recent disclosures, the company’s current growth initiatives and capital deployment strategy are inconclusive based on available public sources.
Geographic Footprint
Akanda Corp. has maintained an international footprint spanning Africa and Europe. Cultivation operations have been located in Lesotho, where the company obtained one of the country’s early cannabis cultivation licenses. This location was selected for favorable climate conditions and regulatory support for export-oriented medical cannabis production.
Commercial distribution activities have been concentrated in Germany, one of the largest and most regulated medical cannabis markets globally. Corporate headquarters and administrative functions have historically been split between the United Kingdom and international subsidiaries. The extent of active operations in each geography has varied over time, and current operational intensity by region is inconclusive based on available public sources.
Leadership & Governance
Akanda Corp. was founded and developed by executives with backgrounds in international cannabis operations, agriculture, and pharmaceuticals. Leadership has emphasized regulatory compliance, pharmaceutical standards, and global market access as core elements of the company’s vision. Governance has been overseen by a board of directors aligned with public company reporting requirements following the Nasdaq listing.
Key executives disclosed in public filings have included:
- Prisoner B. – Chief Executive Officer
- Roger de Souza – Chief Financial Officer
- Paul Smith – Chief Operating Officer
- Gavin Walker – Chairman of the Board
Subsequent changes in executive roles and board composition have been reported intermittently, and the current leadership structure beyond publicly filed disclosures is inconclusive based on available public sources.